Visepegenatide

维培那肽

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug NameVisepegenatide
Drug Alias Name聚乙二醇化艾塞那肽PEG-ExenatidePolyethylene glycol exenatide维派那肽Exenatide pegylated analogue +[8] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2025/11/12
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPeg Bio Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesPDC FZ-LLCTasly (Hong Kong) Pharmaceuticals LtdPeg Bio Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A